Abstract:AIM: To investigate the anti-human hepatocellular car-cinoma (HCC) activity of docetaxel and determine the potential radiosensitizing effect of docetaxel in vivo, and to further explore the mechanism of docetaxel-induced cell growth inhibition, apoptosis and radiosen-sitization at gene level.METHODS: Nude mice bearing HCC with a diameter of about 0.8 cm in the leg received 33 mg/kg docetaxel intraperitoneally, 10 Gy (5 Gy once) tumor irradiation, or both (radiation given 24 and 48 h after docetaxel treatment). The regression and regrowth of the tumors were followed until the tumor diameter reached 1.4 cm approximately. Absolute growth delay (AGD), which was defi ned as the time in days for tumors treated with docetaxel to grow from 0.8 to 1.4 cm in diameter mi-nus the time in days for untreated tumors to reach the same size, was used to evaluate the antitumor effect ofdocetaxel. Normalized growth delay (AGD), which was def ined as the time in days for tumors treated with both docetaxel and irradiation to grow from 0.8 to 1.4 cm in diameter minus the time in days for tumors treated with docetaxel alone to reach the same size, and the en-hancement factor (ratio of NGD to AGD for irradiation alone) was used to assess the effect of the combined docetaxel plus radiation treatment. Real-time qutitative reverse transcription-polymerase chain reaction (RT-PCR) was performed to detect the expression of bcl-2 and p21 genes in HCC cells before and after decetaxel treatment.RESULTS: The tumors in docetaxel treated alone and irradiation treated alone groups needed 35 and 29 d to reach 14 cm in diameter, respectively, while the ones in the control group needed 23 d. So the AGD was 12 and 6 d, respectively. The combined administra-tion of docetaxel and irradiation resulted in signifi cant growth delay (47 d), and the EF was 2.0, indicating that docetaxel enhanced tumor radioresponse. At 20 d, the sizes of the tumors in docetaxel treated alone group and combination of docetaxel and irradiation group were significantly smaller than those in the controls (P = 0.008, P = 0.005), and the size in the combination group was also smaller than that in the irradiation alone group (P = 0.002). Real time quantita-tive RT-PCR analyses revealed that mRNAs of p21 in the docetaxel treated SMMC-7721 cells at most of the time points were increased, as compared with those in the control cells. In contrast, bcl-2 expression in the docetaxel treated SMMC-7721 cells was suppressed as compared with that in the controls.CONCLUSION: Docetaxel can inhibit the growth of HCC and enhance the tumor response to fractionated irradiation in vivo by down-regulation of bcl-2 expres-sion and up-regulation of p21 expression..

The anti-tumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo

The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTX in Vitro and in Vivo.

The Antitumor Effects Of Cik Cells Combined With Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line Spc-A1/Dtx In Vitro And In Vivo

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Preconditioning Chemotherapy With Paclitaxel And Cisplatin Enhances The Antitumor Activity Of Cytokine Induced-Killer Cells In A Murine Lung Carcinoma Model

Gemcitabine Treatment Enhanced the Anti-Tumor Effect of Cytokine Induced Killer Cells by Depletion of CD4+CD25bri Regulatory T Cells

Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.

[The Anti-Tumor Effects of Dendritic Cells Co-Cultured with Cytokine Induced Killer Cells after Chemotherapy].

Preconditioning chemotherapy enhances the antitumor activity of cytokine-induced killer cells in Lewis lung carcinoma model

Effect of anti-CD3-EGFR bispecific antibody-labeled DCCIK immune cells on proliferation of lung cancer cells

Nimotuzumab increased chemosensitivity of human lung adenocarcinoma docetaxel-resistant cell line

Antitumor and radiosensitizing effect of docetaxel on human hepatocellular carcinoma and its mechanisim in vivo

Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer

EFFECT OF RECOMBINANT ADENOVIRUS-p53 COMBINED WITH DOCETAXEL ON THE GROWTH INHIBITION OF HUMAN LUNG ADENOCARCINOMA CELL LINES

Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models

OCT4&SOX2-specific Cytotoxic T Lymphocytes Plus Programmed Cell Death Protein 1 Inhibitor Presented with Synergistic Effect on Killing Lung Cancer Stem-Like Cells in Vitro and Treating Drug-Resistant Lung Cancer Mice in Vivo

Autologous Cytokine-Induced Killer Cell Therapy in Lung Cancer Patients: A Retrospective Study

Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I–II non-small cell lung cancer after curative surgery